JAMIE MORRIS: Open Payments
NPI 1356963953 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,936 in 92 payments from 17 companies in 2025. Trend: 2023 $1,126 · 2024 $1,398 · 2025 $1,936
Food & beverage: $1,936
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $542 |
| Janssen Biotech, Inc. | 13 | $306 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $180 |
| Regeneron Healthcare Solutions, Inc. | 6 | $173 |
| Phathom Pharmaceuticals, Inc. | 8 | $119 |
| Gilead Sciences, Inc. | 6 | $111 |
| Lilly USA, LLC | 5 | $90 |
| Ardelyx, Inc. | 3 | $72 |
| Ipsen Biopharmaceuticals, Inc | 3 | $69 |
| Celltrion USA Inc. | 3 | $63 |
Products named: TREMFYA, RINVOQ, DUPIXENT, ENTYVIO, VOQUEZNA, OMVOH, LINZESS, IBSRELA.
Industry payments across MS — which companies pay providers there.
